Revolution Medicines' Rasonque generates $198 million in sales within five weeks of U.S. approval

Revolution Medicines reported that its pancreatic cancer therapy Rasonque has achieved $198 million in revenue in the first five weeks after receiving U.S. approval. The company said more than 5,000 patients have already been treated with the drug.

The strong commercial start was highlighted on the company’s earnings call, with the chief commercial officer describing the launch as a "strong start."

Analysts had projected lower sales, and the early performance nearly doubled the most optimistic forecasts.

The rapid uptake underscores the demand for new treatments targeting the pan-RAS pathway in pancreatic cancer.